Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
European Urology|June 21, 2002
Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international studyFrans Debruyne, Gary Koch, Peter Boyle, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 18, 2004
[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]Frans Debruyne, Peter Boyle, Fernando Calais da Silva, et al.
European Urology|May 20, 2004
Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysisFrans Debruyne, Peter Boyle, Fernando Calais Da Silva, et al.
European Urology|April 16, 2013
Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological GroupFernando Calais da Silva, Fernando Manuel Calais da Silva, Frederico Gonçalves, et al.
Talanta|January 16, 2018
Dithiothreitol-based protein equalization technology to unravel biomarkers for bladder cancerJ E Araújo, H López-Fernández, M S Diniz, et al.
European Urology|December 26, 2009
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladderRichard J Sylvester, Maurizio A Brausi, Wim J Kirkels, et al.
International Journal of Cancer|January 5, 2002
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trialHarry J de Koning, Anssi Auvinen, Antonio Berenguer Sanchez, et al.
European Urology|July 27, 2015
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-GuérinSamantha Cambier, Richard J Sylvester, Laurence Collette, et al.
Pageof 2